Antihypertensive Drugs Market - Forecasts from 2020 to 2025
The global anti-hypertensive drug market was estimated at US$33.164 billion in the year 2019 and is expected to show a decent growth over the forecast period. The global anti-Hypertensive drug market is poised to surge at a substantial growth over the next five years on the account of the growing prevalence of hypertension across the globe due to the unhealthy lifestyles of the people. Furthermore, the growing geriatric population is also one of the prime factors which is anticipated to augment the demand for these drugs as old people are considerably more susceptible to high blood pressure than young people. Hypertension is also a major cause of premature deaths worldwide.
The other factors contributing to the prevalence of high blood pressure also include excess smoking, stress, chronic kidney disease, excess alcohol consumption, obesity. All these factors play a crucial role in causing high blood pressure in individuals. Thus, due to the growing number of smokers and growing alcohol intake especially among the millennial population group is anticipated to propel the growth opportunities for the market to grow throughout the forecast period and beyond due as the prevalence of hypertension is expected to rise due to these factors. Similarly, the continuously growing proportion of obese population along with the growing prevalence of obesity among the adults is expected to drive the demand for these drugs during the coming years. For instance, according to the World Health Organization, during the year 2016, 13% of the adults were found obese. Similarly, according to the U.S. Department of Health and Human Services, the prevalence of obesity across the adults in the United States was 42.4% in 2017-2018. Out of which more than 40% were men aged 60 and above.
Furthermore, rapid urbanization and globalization are also factors that are deteriorating the conditions of human health. Also, the changing lifestyle of the people along with the rising level of stress is also leading to drive the demand for hypertension drugs. Moreover, the unhealthy lifestyle in terms of eating and sleeping habits of the people also leads to high blood pressure which is also anticipated to positively impact the anti-hypertensive drugs market growth during the next five years.
Rising prevalence of hypertension is driving the market growth
One of the major factors which are significantly driving the demand for these drugs is the globally growing prevalence of hypertension across the globe. The growing number of smokers along with the rising proportion of the population with excessive alcohol intake especially in the underdeveloped economies is boosting the demand for these drugs significantly. According to the data from the World Health Organization, there are around 1.13 billion people with hypertension and major of them live in low and middle-income countries. In addition, the global target of WHO to reduce the prevalence of hypertension by 25% by the year 2025 is also anticipated to boost the demand for these drugs and add up to the market growth significantly. Additionally, the consumption of these drugs is considered highly necessary as one of the highly focused public health challenges because hypertension increases the risk of cardiovascular disease also. Thus, the drugs for controlling the elevated levels of blood pressure reduce the risks of strokes, heart attacks and also heart failures.
Growing geriatric population is also anticipated to drive the demand
The growth in the geriatric population around to globe is considered to also one of the key factors which is anticipated to push the demand for anti-hypertensive drugs during the next five years. There is a significant increase in the aging population is propelling the demand for various drugs as a demographic shift towards an older population is putting a higher burden of various age-associated diseases worldwide. The major factors which are responsible for the growing aging population include increased life expectancy and declining fertility. Also according to the data provided by the United Nations, the number of people age 60 or above is expected to reach 20805 million by 2050 from only 962.3 in 2017. In addition, old people are expected to be more susceptive to suffer from high blood pressure which is expected to propel the demand for these drugs throughout the forecast period and beyond. Moreover, there is a significant increase in the proportion of the geriatric population across the globe. For instance, according to the World Bank Group, the population of ages 65 and above reached 673,618,927 by 2018 from 523,666,170 in 2010. Thereby, anticipated positively impact the market growth in the near future.
Asia Pacific to show robust growth
On the basis of geography, the global anti-hypertensive drugs market has been segmented on the basis of North America, South America, Europe, Middle East and Africa, and Asia Pacific. The market in the Asia Pacific region is projected to show notable growth during the next five years on account of the rising prevalence of hypertension in developing countries such as India and China due to a high number of smokers in and unhealthy lifestyles of the people. In addition, the growing geriatric population in many countries of the APAC region also supports the market growth in the coming years.
North America is anticipated to hold a noteworthy share owing to the presence of the state-of-art healthcare sector. Also, the presence of key market players in the region in countries such as the United States and Canada further supports the significant share of this region throughout the forecast period.
Competitive Insights
Prominent key market players in the anti-Hypertensive drug market include Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc., Sanofi S.A., Merck and Co, and Lupin Pharmaceuticals among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings.
Major players in the global anti-Hypertensive drug market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.
Segmentation
The other factors contributing to the prevalence of high blood pressure also include excess smoking, stress, chronic kidney disease, excess alcohol consumption, obesity. All these factors play a crucial role in causing high blood pressure in individuals. Thus, due to the growing number of smokers and growing alcohol intake especially among the millennial population group is anticipated to propel the growth opportunities for the market to grow throughout the forecast period and beyond due as the prevalence of hypertension is expected to rise due to these factors. Similarly, the continuously growing proportion of obese population along with the growing prevalence of obesity among the adults is expected to drive the demand for these drugs during the coming years. For instance, according to the World Health Organization, during the year 2016, 13% of the adults were found obese. Similarly, according to the U.S. Department of Health and Human Services, the prevalence of obesity across the adults in the United States was 42.4% in 2017-2018. Out of which more than 40% were men aged 60 and above.
Furthermore, rapid urbanization and globalization are also factors that are deteriorating the conditions of human health. Also, the changing lifestyle of the people along with the rising level of stress is also leading to drive the demand for hypertension drugs. Moreover, the unhealthy lifestyle in terms of eating and sleeping habits of the people also leads to high blood pressure which is also anticipated to positively impact the anti-hypertensive drugs market growth during the next five years.
Rising prevalence of hypertension is driving the market growth
One of the major factors which are significantly driving the demand for these drugs is the globally growing prevalence of hypertension across the globe. The growing number of smokers along with the rising proportion of the population with excessive alcohol intake especially in the underdeveloped economies is boosting the demand for these drugs significantly. According to the data from the World Health Organization, there are around 1.13 billion people with hypertension and major of them live in low and middle-income countries. In addition, the global target of WHO to reduce the prevalence of hypertension by 25% by the year 2025 is also anticipated to boost the demand for these drugs and add up to the market growth significantly. Additionally, the consumption of these drugs is considered highly necessary as one of the highly focused public health challenges because hypertension increases the risk of cardiovascular disease also. Thus, the drugs for controlling the elevated levels of blood pressure reduce the risks of strokes, heart attacks and also heart failures.
Growing geriatric population is also anticipated to drive the demand
The growth in the geriatric population around to globe is considered to also one of the key factors which is anticipated to push the demand for anti-hypertensive drugs during the next five years. There is a significant increase in the aging population is propelling the demand for various drugs as a demographic shift towards an older population is putting a higher burden of various age-associated diseases worldwide. The major factors which are responsible for the growing aging population include increased life expectancy and declining fertility. Also according to the data provided by the United Nations, the number of people age 60 or above is expected to reach 20805 million by 2050 from only 962.3 in 2017. In addition, old people are expected to be more susceptive to suffer from high blood pressure which is expected to propel the demand for these drugs throughout the forecast period and beyond. Moreover, there is a significant increase in the proportion of the geriatric population across the globe. For instance, according to the World Bank Group, the population of ages 65 and above reached 673,618,927 by 2018 from 523,666,170 in 2010. Thereby, anticipated positively impact the market growth in the near future.
Asia Pacific to show robust growth
On the basis of geography, the global anti-hypertensive drugs market has been segmented on the basis of North America, South America, Europe, Middle East and Africa, and Asia Pacific. The market in the Asia Pacific region is projected to show notable growth during the next five years on account of the rising prevalence of hypertension in developing countries such as India and China due to a high number of smokers in and unhealthy lifestyles of the people. In addition, the growing geriatric population in many countries of the APAC region also supports the market growth in the coming years.
North America is anticipated to hold a noteworthy share owing to the presence of the state-of-art healthcare sector. Also, the presence of key market players in the region in countries such as the United States and Canada further supports the significant share of this region throughout the forecast period.
Competitive Insights
Prominent key market players in the anti-Hypertensive drug market include Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc., Sanofi S.A., Merck and Co, and Lupin Pharmaceuticals among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings.
Major players in the global anti-Hypertensive drug market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.
Segmentation
- By Drug Class
- Diuretics
- Beta-Blockers
- ACI Inhibitors
- Calcium Channel Blockers
- Combined Alpha and Beta-Blockers
- Others
- By Type
- Primary Hypertension
- Secondary Hypertension
- By Sales Channel
- Prescription
- Over-the-counter (OTC)
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- France
- United Kingdom
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- Others
- Asia Pacific
- China
- Japan
- South Korea
- India
- Others
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Product Pipeline
4.5. Industry Value Chain Analysis
5. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET ANALYSIS, BY DRUG CLASS
5.1. Introduction
5.2. Diuretics
5.3. Beta-Blockers
5.4. ACI Inhibitors
5.5. Calcium Channel Blockers
5.6. Combined Alpha and Beta-Blockers
5.7. Others
6. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET ANALYSIS, BY TYPE
6.1. Introduction
6.2. Primary Hypertension
6.3. Secondary Hypertension
7. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET ANALYSIS, BY SALES CHANNEL
7.1. Introduction
7.2. Prescription
7.3. Over-the-counter (OTC)
8. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET ANALYSIS, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. North America Anti-Hypertensive Drug Market, By Drug Class
8.2.2. North America Anti-Hypertensive Drug Market, By Type
8.2.3. North America Anti-Hypertensive Drug Market, By Sales Channel
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. South America Anti-Hypertensive Drug Market, By Drug Class
8.3.2. South America Anti-Hypertensive Drug Market, By Type
8.3.3. South America Anti-Hypertensive Drug Market, By Sales Channel
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. Europe Anti-Hypertensive Drug Market, By Drug Class
8.4.2. Europe Anti-Hypertensive Drug Market, By Type
8.4.3. Europe Anti-Hypertensive Drug Market, By Sales Channel
8.4.4. By Country
8.4.4.1. Germany
8.4.4.2. France
8.4.4.3. United Kingdom
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. Middle East and Africa Anti-Hypertensive Drug Market, By Drug Class
8.5.2. Middle East and Africa Anti-Hypertensive Drug Market, By Type
8.5.3. Middle East and Africa Anti-Hypertensive Drug Market, By Sales Channel
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. Israel
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. Asia Pacific Anti-Hypertensive Drug Market, By Drug Class
8.6.2. Asia Pacific Anti-Hypertensive Drug Market, By Type
8.6.3. Asia Pacific Anti-Hypertensive Drug Market, By Sales Channel
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. South Korea
8.6.4.4. India
8.6.4.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. AstraZeneca
10.2. Boehringer Ingelheim International GmbH
10.3. DAIICHI SANKYO COMPANY, LIMITED
10.4. Novartis AG
10.5. Pfizer Inc.
10.6. Johnson & Johnson Services, Inc.
10.7. Merck and Co. Inc.
10.8. Lupin Pharmaceuticals, Inc.
10.9. Sanofi S.A.
10.10. Sun Pharmaceutical Industries Ltd.
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Product Pipeline
4.5. Industry Value Chain Analysis
5. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET ANALYSIS, BY DRUG CLASS
5.1. Introduction
5.2. Diuretics
5.3. Beta-Blockers
5.4. ACI Inhibitors
5.5. Calcium Channel Blockers
5.6. Combined Alpha and Beta-Blockers
5.7. Others
6. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET ANALYSIS, BY TYPE
6.1. Introduction
6.2. Primary Hypertension
6.3. Secondary Hypertension
7. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET ANALYSIS, BY SALES CHANNEL
7.1. Introduction
7.2. Prescription
7.3. Over-the-counter (OTC)
8. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET ANALYSIS, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. North America Anti-Hypertensive Drug Market, By Drug Class
8.2.2. North America Anti-Hypertensive Drug Market, By Type
8.2.3. North America Anti-Hypertensive Drug Market, By Sales Channel
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. South America Anti-Hypertensive Drug Market, By Drug Class
8.3.2. South America Anti-Hypertensive Drug Market, By Type
8.3.3. South America Anti-Hypertensive Drug Market, By Sales Channel
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. Europe Anti-Hypertensive Drug Market, By Drug Class
8.4.2. Europe Anti-Hypertensive Drug Market, By Type
8.4.3. Europe Anti-Hypertensive Drug Market, By Sales Channel
8.4.4. By Country
8.4.4.1. Germany
8.4.4.2. France
8.4.4.3. United Kingdom
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. Middle East and Africa Anti-Hypertensive Drug Market, By Drug Class
8.5.2. Middle East and Africa Anti-Hypertensive Drug Market, By Type
8.5.3. Middle East and Africa Anti-Hypertensive Drug Market, By Sales Channel
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. Israel
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. Asia Pacific Anti-Hypertensive Drug Market, By Drug Class
8.6.2. Asia Pacific Anti-Hypertensive Drug Market, By Type
8.6.3. Asia Pacific Anti-Hypertensive Drug Market, By Sales Channel
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. South Korea
8.6.4.4. India
8.6.4.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. AstraZeneca
10.2. Boehringer Ingelheim International GmbH
10.3. DAIICHI SANKYO COMPANY, LIMITED
10.4. Novartis AG
10.5. Pfizer Inc.
10.6. Johnson & Johnson Services, Inc.
10.7. Merck and Co. Inc.
10.8. Lupin Pharmaceuticals, Inc.
10.9. Sanofi S.A.
10.10. Sun Pharmaceutical Industries Ltd.
